Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2014

Specialty Pharmacy Updates 


Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications.

Name Indication Coverage Available From
Valchlor (mechlorethamine)  Valchlor is an alkylating drug used for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.  Pharmacy Benefit  Accredo Pharmacy
Opsumit (macitentan)  Opsumit is an oral endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension. Pharmacy Benefit  Accredo Pharmacy
Imbruvica (ibrutinib)  Imbruvica is used to treat mantle cell lymphoma (MCL) in individuals who have received at least one prior treatment. Pharmacy Benefit  Diplomat Pharmacy
Adempas (riociguat)
 
Ademas is used to treat chronic thromboembolic pulmonary hypertension and  pulmonary arterial hypertension.  Pharmacy Benefit  Accredo Pharmacy
Gilotrif (afatinib dimaleate)  Gilotrif is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer.  Pharmacy Benefit  Accredo Pharmacy
zoledronic acid (Reclast)  Zoledronic acid is a bisphosphonate used to prevent and treat osteoporosis or to treat Paget’s disease of bone in men and women. Medical Benefit  ICORE Pharmacy

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Commitment to the Principles of Centered Care

Reminder: Electronic Funds Transfer is Now Available

CLINICIAN CORNER

Update: Aloxi, Anzemet, and Emend Prior Authorization Medial Review Criteria

New Medical Policy: Cell-free Fetal DNA Testing

Medical Policy for Genetic Testing

Reminder: Measures Aimed at Boosting SNF/PCP Care Coordination

P&T Committee Updates

Specialty Pharmacy Updates

Club Drugs: Emerging Trends and Patterns

OFFICE ASSISTANT

2014 Fee Schedule Updates

Update: Gastroenterology Payment Policy

New CMS 1500 Claim Form Now Accepted

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Kristin Edmonston,
Production Coordinator